Stoke Therapeutics Inc (STOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has a cash flow conversion efficiency ratio of -0.099x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.37 Million) by net assets ($308.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Stoke Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Stoke Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Stoke Therapeutics Inc for a breakdown of total debt and financial obligations.
Stoke Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stoke Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bellring Brands LLC
NYSE:BRBR
|
0.006x |
|
Silicon2 Co. Ltd.
KQ:257720
|
0.069x |
|
Dongguan Eontec Co Ltd
SHE:300328
|
-0.045x |
|
Shandong Sacred Sun Power Sources Co Ltd
SHE:002580
|
0.017x |
|
Mesoblast Ltd
NASDAQ:MESO
|
-0.027x |
|
Sirius Real Estate Ltd
JSE:SRE
|
0.019x |
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SHG:600389
|
0.047x |
|
Mednax Inc
NYSE:MD
|
0.154x |
Annual Cash Flow Conversion Efficiency for Stoke Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see STOK market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $229.02 Million | $-86.85 Million | -0.379x | +25.36% |
| 2023-12-31 | $159.56 Million | $-81.07 Million | -0.508x | -194.71% |
| 2022-12-31 | $184.85 Million | $-31.87 Million | -0.172x | +43.89% |
| 2021-12-31 | $217.78 Million | $-66.91 Million | -0.307x | -108.17% |
| 2020-12-31 | $286.08 Million | $-42.22 Million | -0.148x | -6.66% |
| 2019-12-31 | $224.43 Million | $-31.05 Million | -0.138x | -32.60% |
| 2018-12-31 | $105.07 Million | $-10.96 Million | -0.104x | -102.50% |
| 2017-12-31 | $-1.29 Million | $-5.38 Million | 4.167x | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more